New pill aims to slow vision loss in rare usher syndrome
NCT ID NCT04355689
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study tests whether NPI-001 tablets can safely slow or stop vision loss in people with Usher syndrome, a rare genetic condition that causes blindness and hearing loss. About 49 adults will take either the study drug or a placebo for 24 months. The main goal is to see if the drug helps preserve retinal sensitivity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CERA
Melbourne, Australia
-
Lions Eye Institute
Perth, Australia
-
Queensland Eye Institute
Brisbane, Australia
-
Sydney Eye Hospital / Save Sight Institute
Sydney, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single eye injection restore sight in genetic blindness?
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Stem cell eye transplant aims to halt blindness from rare genetic disease
- Could stem cells restore sight in damaged eyes?
- Gene therapy injection aims to restore sight in rare blindness
- Ground-Level vision test could help retinitis pigmentosa patients walk better